Genprex, Inc. (GNPX): Shareholders' Equity
$7.96M
As of 2025-12-31
$14.80M
As of 2026-06-30
-29.0%
3-year compound annual growth
-23.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.96M | +391.4% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $1.62M | -78.2% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $7.42M | -66.7% | 2025-04-01, Balance as of period end |
| 2022-12-31 | $22.27M | n/a | 2024-04-01, Balance as of period end |
| 2022-09-30 | $27.49M | n/a | 2023-03-31, Balance as of period end |
| 2022-06-30 | $32.41M | n/a | 2023-03-31, Balance as of period end |
| 2021-12-31 | $41.28M | +33.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $30.92M | +922.5% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $3.02M | -66.0% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $8.88M | n/m | 2020-03-30, Balance as of period end |
| 2017-12-31 | $428.6K | -73.6% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $1.62M | n/a | 2018-04-17, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Genprex, Inc. (GNPX) | 2025-12-31 | $7.96M | +391.4% |
| Oragenics Inc (OGEN) | 2025-12-31 | $8.28M | n/m |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $37.3K | -98.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $5.67M | -74.1% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $9.09M | +2.7% |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | -$9.02M | n/m |
| Nanoviricides, Inc. (NNVC) | 2026-06-30 | $8.68M | +15.5% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $2.25M | +217.9% |
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | -$629.0K | n/m |
Compare GNPX, OGEN, MDCX, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗